H19 and metabolic dysfunction-associated steatohepatitis: Another weakness is that the high degree of heterogeneity in the disease severity or HCC-associated clinical manifestations, such as viral hepatitis as well as with alcoholic and non-alcoholic steatohepatitis within HCC patients may result in distinct findings regarding the link between H19 gene polymorphisms and liver tumorigenesis.